Actively Recruiting
Long-Term Study of Ritlecitinib Safety and Effects in Children With Severe Alopecia Areata Following Previous Pediatric Studies
Led by Pfizer · Updated on 2026-10-15
140
Participants Needed
67
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the long-term safety and effects of the medicine ritlecitinib in children with severe alopecia areata, a condition that causes significant hair loss. This Phase 3 study involves participants who have completed previous pediatric studies on ritlecitinib and aims to assess the drugs safety, tolerability, and effectiveness over an extended period. Participants will take ritlecitinib capsules by mouth once daily at home. Those who received different doses in prior studies will continue with the same dose or be randomly assigned to higher or lower doses in this trial. The study lasts up to 3 years, during which participants may be switched to placebo if they do not meet treatment continuation criteria. Throughout the study, participants will attend 17 clinic visits and receive monthly phone calls for monitoring. Researchers will evaluate safety by tracking side effects and serious adverse events. Effectiveness will be measured using tools like the Severity of Alopecia Tool SALT scores, eyebrow and eyelash assessments, and various patient-reported outcomes. Assessments will occur regularly to observe changes and impacts on quality of life.
CONDITIONS
Brief Title
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here